Tevimbra is under clinical development by BeiGene and currently in Phase II for Marginal Zone B-cell Lymphoma.

The FDA has granted Breakthrough Therapy Designation to Bayer’s PI3K inhibitor Aliqopa (copanlisib) for marginal zone lymphoma (MZL) patients who have received two prior therapies. MZL is an ...

At the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition last month, the company announced positive ...

Calquence is under clinical development by AstraZeneca and currently in Phase II for Nodal Marginal Zone B-Cell Lymphoma.

Some lymphomas grow and spread slowly (described as 'indolent'), for example follicular lymphoma and marginal zone lymphoma. Others are faster growing ('aggressive'), for example, diffuse large B ...

Medically reviewed by Gagandeep Brar, MD Skin (cutaneous) lymphomas often manifest as a skin rash. Although usually ...

Brukinsa has been growing particularly quickly, thanks to broad labelling across previously treated MCL and various lines of therapy for CLL, WM, marginal zone lymphoma (MZL), and follicular ...

The study evaluated Yescarta in patients with relapsed/refractory non-NHL, including follicular lymphoma or marginal zone lymphoma. The data was presented at the 66th American Society of ...

Eligible disease subtypes include large B-cell lymphoma, follicular lymphoma grade 1-3a, marginal zone lymphoma, and mantle cell lymphoma/ CTX112 was infused after a standard course of ...

During the 66th American Society of Hematology Annual Meeting and Exposition, investigators revealed early-phase 1 data evaluating various BTK degraders that leverage different strategies to overcome ...

Systemic treatment strategies lower the risk for new Sjögren’s disease activity when there are complications with marginal zone lymphoma, according to a study published in The Lancet Rheumatology.

Verismo Therapeutics, a clinical-stage CAR T company developing novel KIR-CAR platform technology, today announced that it ...